MTRR Individual Gene-Cell Science Systems Kit:
Note: This is a test kit that will be mailed to you. It can be performed using a swab or a blood draw. Unless we are told otherwise, the swabs will be sent to you. It is your responsibility to arrange for the blood draw for your kit should you choose the blood draw.
Fasting Required: No
Lab: Cell Science Systems
Specimen: Swab (Blood - by request only.)
Results: Average processing time 10-15 Business days
Note: Result turnaround times are an estimate and are not guaranteed. Our reference lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.
Medication and Supplement Instructions for CSS Testing:
- Testing does not need to be delayed because of medication or supplement use.
- Medications that are part of your daily routine should be continued as they are considered part of your normal physiological state.
- If possible, please avoid taking any oral medications, IV infusions, intramuscular (IM) injections, or oral supplements for 4 hours before blood draw.
- If you are taking medications that may impact white blood cell counts, it is recommended to collect an additional blood tube at the time of your draw.
- For short term medications (such as antibiotics) that will be discontinued, it is best to wait at least 2 weeks after completing the medication before completing your blood draw.
- If you are taking methylene blue, it is recommended to wait at least 72 hours after your last dose before proceeding with your blood draw for the Cellular Nutrition Assay.
- Fasting is not necessary
Description: The MTRR gene encodes the enzyme methionine synthase reductase (MSR). Its task is to support MS in the remethylation of homocysteine into methionine by keeping the MS enzyme in an active (reduced) form (see MTR). Over time, MS becomes oxidized and loses its ability to transfer methyl groups from the MS-methylcobalamin complex to homocysteine. The MS has to be activated (reduced) again by MSR in a so called “ping-pong” reaction that uses SAMe (S-adenosyl methionine) as the activating (reducing) agent.
The common MTRR polymorphism, A66G, has a prevalence of 26.58% (GG), 48.84 %(AG), 24.58% (AA) in the Caucasian population. In combination with the C677T polymorphism in MTHFR, MTRR genotypes AG, GG influence total plasma homocysteine levels. Additionally, the combination of the genetic polymorphisms in MTRR and MTHFR was linked to an increase in DNA damage as measured by micronucleus frequency (MN).